GT200100211AA - COMPOSITES OF IMIDAZOL CONDENSED WITH ARILO OR HETEROARILO AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS. (PATENTEFRACTIONARY NO. 1 OF THE INVENTION PATENT APPLICATION NO. PI-2001-0211. - Google Patents

COMPOSITES OF IMIDAZOL CONDENSED WITH ARILO OR HETEROARILO AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS. (PATENTEFRACTIONARY NO. 1 OF THE INVENTION PATENT APPLICATION NO. PI-2001-0211.

Info

Publication number
GT200100211AA
GT200100211AA GT200100211AK GT200100211K GT200100211AA GT 200100211A A GT200100211A A GT 200100211AA GT 200100211A K GT200100211A K GT 200100211AK GT 200100211 K GT200100211 K GT 200100211K GT 200100211A A GT200100211A A GT 200100211AA
Authority
GT
Guatemala
Prior art keywords
heteroarilo
arilo
imidazol
condensed
patentefractionary
Prior art date
Application number
GT200100211AK
Other languages
Spanish (es)
Inventor
Kazunari Nakao
Yoshiyuki Okumura
Miyako Matsumizu
Naomi UENO
Yoshinobu Hashizumo
Tomoki Kato
Akiyoshi Kawai
Seiji Nukui
Katsuchiro Shinjyo
Kana Taniguchi
Yoriko Mayake
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200100211AA publication Critical patent/GT200100211AA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE IMIDAZOL CONDENSADO CON ARILO O HETEROARILO, O A SUS SALES FARMACEUTICAMENTE ACEPTABLES, A COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y A SUS USOS MEDICOS. LOS COMPUESTOS DE ESTA INVENCION TIENEN ACTIVIDAD COMO ANTAGONISTAS DEL RECEPTOR DELA PROTAGLANDINA E2 Y SON UTILES EN EL TRATAMIENTO O ALIVIO DEL DOLOR, DE LA INFLAMACION, TALES COMO LA ARTRITIS Y EN EL TRATAMIENTO O PREVENCION DE TRASTORNOS O AFECCIONES MEDICAS SELECCIONADAS ENTRE DOLOR, ENFERMEDADES INFLAMATORIAS Y SIMILARES.THE PRESENT INVENTION REFERS TO IMIDAZOL COMPOUNDS CONDENSED WITH ARILO OR HETEROARILO, OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR MEDICAL USES. THE COMPOUNDS OF THIS INVENTION HAVE ACTIVITY AS ANTAGONISTS OF THE RECEIVER DELA PROTAGLANDINA E2 AND ARE USEFUL IN THE TREATMENT OR RELIEF OF THE PAIN, OF THE INFLAMMATION, SUCH AS THE ARTHRITIS AND IN THE TREATMENT OR PREVENTION OF NURSING DRUGS AND SIMILAR.

GT200100211AK 2000-10-19 2001-10-19 COMPOSITES OF IMIDAZOL CONDENSED WITH ARILO OR HETEROARILO AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS. (PATENTEFRACTIONARY NO. 1 OF THE INVENTION PATENT APPLICATION NO. PI-2001-0211. GT200100211AA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24182500P 2000-10-19 2000-10-19

Publications (1)

Publication Number Publication Date
GT200100211AA true GT200100211AA (en) 2004-11-30

Family

ID=22912331

Family Applications (2)

Application Number Title Priority Date Filing Date
GT200100211AK GT200100211AA (en) 2000-10-19 2001-10-19 COMPOSITES OF IMIDAZOL CONDENSED WITH ARILO OR HETEROARILO AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS. (PATENTEFRACTIONARY NO. 1 OF THE INVENTION PATENT APPLICATION NO. PI-2001-0211.
GT200100211A GT200100211A (en) 2000-10-19 2001-10-19 IMIDAZOL COMPOUNDS CONDENSED WITH ARILO OR HETEROARILO AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS.

Family Applications After (1)

Application Number Title Priority Date Filing Date
GT200100211A GT200100211A (en) 2000-10-19 2001-10-19 IMIDAZOL COMPOUNDS CONDENSED WITH ARILO OR HETEROARILO AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS.

Country Status (49)

Country Link
US (4) US6710054B2 (en)
EP (3) EP1326606A2 (en)
JP (3) JP2004511518A (en)
KR (2) KR20030048060A (en)
CN (3) CN101967146B (en)
AP (2) AP2003002806A0 (en)
AR (1) AR035498A1 (en)
AT (1) ATE320428T1 (en)
AU (3) AU1079602A (en)
BG (2) BG107699A (en)
BR (2) BRPI0114704B8 (en)
CA (2) CA2426457C (en)
CR (2) CR6951A (en)
CY (1) CY1105035T1 (en)
CZ (2) CZ2003979A3 (en)
DE (1) DE60118020T2 (en)
DK (1) DK1326864T3 (en)
DO (1) DOP2001000271A (en)
DZ (1) DZ3513A1 (en)
EA (2) EA005991B1 (en)
EC (2) ECSP034563A (en)
EE (2) EE200300188A (en)
ES (2) ES2524586T3 (en)
GE (1) GEP20053673B (en)
GT (2) GT200100211AA (en)
HN (1) HN2001000224A (en)
HR (1) HRP20030269A2 (en)
HU (2) HUP0600593A3 (en)
IL (2) IL155439A0 (en)
IS (2) IS6765A (en)
MA (2) MA26952A1 (en)
MX (2) MXPA03003463A (en)
NO (2) NO20031582L (en)
NZ (1) NZ525163A (en)
OA (2) OA12526A (en)
PA (1) PA8531001A1 (en)
PE (1) PE20020548A1 (en)
PL (2) PL365781A1 (en)
PT (1) PT1326864E (en)
SI (1) SI1326864T1 (en)
SK (2) SK4602003A3 (en)
SV (1) SV2002000696A (en)
TN (1) TNSN01145A1 (en)
TW (2) TWI294424B (en)
UA (1) UA74391C2 (en)
UY (1) UY26977A1 (en)
WO (2) WO2002032422A2 (en)
YU (1) YU31303A (en)
ZA (2) ZA200302722B (en)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544511B2 (en) * 1996-09-25 2009-06-09 Neuralstem Biopharmaceuticals Ltd. Stable neural stem cell line methods
JP4310109B2 (en) * 2001-04-26 2009-08-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 Nitrogen-containing fused ring compound having pyrazolyl group as substituent and pharmaceutical composition thereof
JP2005522491A (en) 2002-04-12 2005-07-28 ファイザー株式会社 Imidazole compounds as anti-inflammatory and analgesic agents
WO2003087061A1 (en) * 2002-04-12 2003-10-23 Pfizer Japan Inc. Pyrazole compounds as anti-inflammatory and analgesic agents
NZ535748A (en) * 2002-04-12 2007-06-29 Pfizer Use of EP4 receptor ligands in the treatment of IL-6 involved diseases
AU2003293409A1 (en) * 2002-12-09 2004-06-30 Karl K. Johe Method for discovering neurogenic agents
US8293488B2 (en) 2002-12-09 2012-10-23 Neuralstem, Inc. Method for screening neurogenic agents
MXPA05006656A (en) * 2002-12-20 2006-02-22 Dynogen Pharmaceuticals Inc METHODS OF TREATING NON-PAINFUL BLADDER DISORDERS USING alpha2.
WO2004072019A1 (en) * 2003-02-14 2004-08-26 Wako Pure Chemical Industries, Ltd. Method for producing hydroxylamine compound using platinum catalyst fixed on ion exchange resin
EP2174933B1 (en) * 2003-03-13 2019-04-03 Idemitsu Kosan Co., Ltd. Benzimidazole derivatives for use in organic electroluminescent devices
US20070105931A1 (en) * 2003-08-04 2007-05-10 Mayo Foundation For Medical Education And Research Methods and compositions for inhibiting the proliferation of prostate cancer cells
FR2860514A1 (en) * 2003-10-03 2005-04-08 Sanofi Synthelabo ARYLALKYLCARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
DE602004025636D1 (en) * 2003-12-23 2010-04-01 Roche Diagnostics Gmbh Method for the evaluation of rheumatoid arthritis by determination of anti-CCP and interleukin 6
MXPA06012172A (en) * 2004-04-20 2007-01-17 Pfizer Prod Inc Combinations comprising alpha-2-delta ligands.
US7271271B2 (en) * 2004-06-28 2007-09-18 Amgen Sf, Llc Imidazolo-related compounds, compositions and methods for their use
US7691629B2 (en) 2004-11-17 2010-04-06 Neuralstem, Inc. Transplantation of human neural cells for treatment of neurodegenerative conditions
WO2006063466A1 (en) * 2004-12-17 2006-06-22 Merck Frosst Canada Ltd. 2-(phenyl or heterocyclic)-1h-phenantrho[9,10-d]imidazoles as mpges-1 inhibitors
US7442716B2 (en) * 2004-12-17 2008-10-28 Merck Frosst Canada Ltd. 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
BRPI0608819B8 (en) * 2005-03-11 2021-05-25 Askat Inc crystal forms of an imidazole derivative
WO2007073405A1 (en) * 2005-12-21 2007-06-28 Decode Genetics Ehf N-linked aryl heteroaryl inhibitors of lta4h for treating inflammation
EP2019675A4 (en) * 2006-05-02 2011-03-02 Merck Frosst Canada Ltd Methods for treating or preventing neoplasias
CL2007002994A1 (en) * 2006-10-19 2008-02-08 Wyeth Corp HETEROCICLIC DERIVATIVE COMPOUNDS CONTAINING SULFAMOIL, INHIBITORS OF HSP90; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF CANCER, SUCH AS CANCER OF BREAST, COLON AND PROSTATE, BETWEEN OTHERS.
WO2008116304A1 (en) * 2007-03-26 2008-10-02 Merck Frosst Canada Ltd. Naphthalene and quinoline sulfonylurea derivatives as ep4 receptor antagonists
DE102007037579B4 (en) 2007-08-09 2012-05-16 Emc Microcollections Gmbh New benzimidazol-2-yl-alkylamines and their use as microbicidal agents
WO2009029622A2 (en) 2007-08-27 2009-03-05 Siga Technologies, Inc. Antiviral drugs for treatment of arenavirus infection
EP2265581A1 (en) 2008-01-22 2010-12-29 Oxagen Limited Compounds having crth2 antagonist activity
JP2012503605A (en) * 2008-09-25 2012-02-09 メルク カナダ インコーポレイテッド Beta-carboline sulfonylurea derivatives as EP4 receptor antagonists
EP2392323A4 (en) 2009-01-30 2012-09-26 Univ Kyoto Prostate cancer progression inhibitor and progression inhibition method
CN102421429B (en) 2009-04-22 2016-08-17 拉夸里亚创药株式会社 Selective ep 4 receptor agonistic substance for treatment of cancer
KR101041561B1 (en) * 2009-12-21 2011-06-15 짚라인코리아 (주) Wearing device for flying
US9457084B2 (en) * 2010-02-22 2016-10-04 Raqualia Pharma Inc. Use of EP4 receptor antagonists in the treatment of IL-23 mediated diseases
SG187226A1 (en) 2010-07-28 2013-03-28 Neuralstem Inc Methods for treating and/or reversing neurodegenerative diseases and/or disorders
HUE031408T2 (en) 2010-09-21 2017-07-28 Eisai R&D Man Co Ltd Pharmaceutical composition
JPWO2012102254A1 (en) * 2011-01-25 2014-06-30 キッセイ薬品工業株式会社 Indole derivatives or pharmacologically acceptable salts thereof
TW201326154A (en) * 2011-11-28 2013-07-01 拜耳知識產權公司 Novel 2H-indazoles as EP2 receptor antagonists
UA115576C2 (en) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт BENZIMIDASOL DERIVATIVES AS ER4 ANGAGONES
US10391086B2 (en) 2013-03-19 2019-08-27 Askat Inc. Use of EP4 receptor antagonists in the treatment of cartilage disease
CN107496421A (en) * 2013-03-19 2017-12-22 株式会社ＡｓｋＡｔ Purposes of the EP4 receptor antagonists in the treatment of cartilage disease
WO2014153280A1 (en) * 2013-03-22 2014-09-25 Merck Sharp & Dohme Corp. 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
EP3040329B1 (en) * 2013-08-29 2018-10-10 Kyoto Pharmaceutical Industries, Ltd. Aromatic compound and use thereof in the treatment of disorders associated with bone metabolism
TW201607943A (en) 2013-12-19 2016-03-01 拜耳製藥公司 Novel benzimidazole derivatives as EP4 ligands
PT3113774T (en) * 2014-03-06 2022-02-28 Elanco Animal Health Incorporated Compositions of grapiprant and methods for using the same
ES2919346T3 (en) 2014-03-06 2022-07-26 Elanco Animal Health Incorporated Crystal form x2 of grapiprant
KR102100021B1 (en) 2014-10-20 2020-04-13 뉴럴스템, 인크. Stable neural stem cells comprising an exogenous polynucleotide coding for a growth factor and methods of use thereof
US12109218B2 (en) 2014-12-09 2024-10-08 Aratana Therapeutics, Inc. Compositions of grapiprant and methods for using the same
US10421756B2 (en) 2015-07-06 2019-09-24 Rodin Therapeutics, Inc. Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
US20180194769A1 (en) 2015-07-06 2018-07-12 Rodin Therapeutics, Inc. Hetero-halo inhibitors of histone deacetylase
CR20180323A (en) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd DERIVATIVES OF INDOL N-SUBSTITUTES AS MODULATORS OF PGE2 RECEIVERS
CN105486851A (en) * 2015-11-20 2016-04-13 中国药科大学 Fluorescence resonance energy transfer technology-based prostaglandin receptor screening model
US10342785B2 (en) 2016-11-04 2019-07-09 Askat Inc. Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
SI3570834T1 (en) 2017-01-11 2022-05-31 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
WO2018162562A1 (en) 2017-03-10 2018-09-13 Bayer Pharma Aktiengesellschaft Use of an ep4 antagonist for the treatment of inflammatory pain
AR111874A1 (en) 2017-05-18 2019-08-28 Idorsia Pharmaceuticals Ltd PIRIMIDINE DERIVATIVES
PE20191814A1 (en) 2017-05-18 2019-12-27 Idorsia Pharmaceuticals Ltd PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS
LT3625228T (en) 2017-05-18 2021-10-25 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives as pge2 receptor modulators
WO2018210987A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as pge2 receptor modulators
SI3625224T1 (en) 2017-05-18 2021-11-30 Idorsia Pharmaceuticals Ltd N-substituted indole derivatives
HUE058799T2 (en) 2017-08-07 2022-09-28 Alkermes Inc Bicyclic inhibitors of histone deacetylase
WO2019038156A1 (en) 2017-08-22 2019-02-28 Bayer Pharma Aktiengesellschaft Use of an ep4 antagonist for the treatment of arthritis
RU2659169C1 (en) * 2017-10-31 2018-06-28 Федеральное бюджетное учреждение науки "Уфимский научно-исследовательский институт медицины труда и экологии человека" Method for predicting the risk of development of immuno-mediated diseases in person working in work zone at the conditions of air contamination by opportunistic pathogens
EP3781162A1 (en) 2018-04-16 2021-02-24 Arrys Therapeutics, Inc. Ep4 inhibitors and use thereof
WO2019245590A1 (en) 2018-06-18 2019-12-26 Avista Pharma Solutions, Inc. Chemical compounds
JP2021530487A (en) * 2018-07-11 2021-11-11 アリーズ セラピューティクス， インコーポレイテッド EP4 inhibitor and its synthesis
US20210315909A1 (en) * 2018-07-11 2021-10-14 Arrys Therapeutics, Inc. Polymorphic compounds and uses thereof
JP2022508648A (en) 2018-10-05 2022-01-19 アンナプルナ バイオ インコーポレイテッド Compounds and compositions for treating conditions associated with APJ receptor activity
US11512088B2 (en) 2019-01-30 2022-11-29 Avista Pharma Solutions, Inc. Synthetic process and intermediates
US11459331B2 (en) 2019-01-30 2022-10-04 Avista Pharma Solutions, Inc. Chemical compounds
WO2021027722A1 (en) * 2019-08-09 2021-02-18 成都先导药物开发股份有限公司 Immunomodulator
US11254675B2 (en) 2019-08-12 2022-02-22 Cadila Healthcare Limited Process for preparation of grapiprant
WO2021226162A1 (en) 2020-05-05 2021-11-11 Arrys Therapeutics, Inc. Ep4 antagonists and their use in the treatment of proliferative diseases
EP4245301A4 (en) 2020-11-13 2024-08-21 Ono Pharmaceutical Co Cancer treatment by combined use of ep4 antagonist and immune checkpoint inhibitor
CN116478155A (en) * 2022-01-17 2023-07-25 洛阳惠中兽药有限公司 Preparation method of grapiprant and intermediate thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8804439D0 (en) * 1988-02-25 1988-03-23 Pfizer Ltd Dihydropyridines
IL94805A (en) 1989-06-28 1994-04-12 Ciba Geigy Ag (Arylsulfonamido- and pyridyl- or imidazolyl-)-substituted carboxylic acids, processfor their preparation and pharmaceutical compositions containing them
GB9009469D0 (en) * 1990-04-27 1990-06-20 British Bio Technology Compounds
GB9010404D0 (en) * 1990-05-09 1990-06-27 Pfizer Ltd Therapeutic agents
GB2330307A (en) 1998-02-07 1999-04-21 Glaxo Group Ltd EP4 Receptor antagonists as bone resorption inhibitors
WO1999047497A2 (en) * 1998-03-13 1999-09-23 Merck Frosst Canada & Co. Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
WO2000021532A1 (en) * 1998-10-15 2000-04-20 Merck & Co., Inc. Methods for inhibiting bone resorption
JP2002527400A (en) 1998-10-15 2002-08-27 メルク エンド カムパニー インコーポレーテッド How to stimulate bone formation
JP2000191615A (en) * 1998-10-20 2000-07-11 Takeda Chem Ind Ltd Aromatic amine derivative, its production and agent
WO2000064880A1 (en) 1999-04-22 2000-11-02 Synaptic Pharmaceutical Corporation Selective npy (y5) antagonists
BR0010605A (en) 1999-04-28 2002-02-13 Aventis Pharma Gmbh Acid derivatives of di-aryl as ligands for ppar receptors
GB0031295D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Naphthalene derivatives
GB0031302D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Napthalene derivatives
GB0031315D0 (en) 2000-12-21 2001-02-07 Glaxo Group Ltd Indole derivatives

Also Published As

Publication number Publication date
JP4060182B2 (en) 2008-03-12
AR035498A1 (en) 2004-06-02
MA26952A1 (en) 2004-12-20
US20020107273A1 (en) 2002-08-08
BR0114758A (en) 2003-07-01
JP4703607B2 (en) 2011-06-15
CZ20031010A3 (en) 2004-12-15
EA200300391A1 (en) 2003-10-30
ECSP034569A (en) 2003-06-25
EE200300190A (en) 2003-10-15
ECSP034563A (en) 2003-06-25
SV2002000696A (en) 2002-12-02
CA2426457C (en) 2010-01-05
MXPA03003463A (en) 2003-07-14
IL155438A0 (en) 2003-11-23
YU31303A (en) 2006-05-25
BG107732A (en) 2004-01-30
CZ2003979A3 (en) 2004-05-12
IS6785A (en) 2003-04-14
NZ525163A (en) 2005-09-30
MA26955A1 (en) 2004-12-20
WO2002032422A3 (en) 2002-07-25
NO20031582L (en) 2003-06-17
UA74391C2 (en) 2005-12-15
NO20031658L (en) 2003-06-10
SK4432003A3 (en) 2004-08-03
EA005991B1 (en) 2005-08-25
ES2524586T3 (en) 2014-12-10
SI1326864T1 (en) 2006-10-31
OA12526A (en) 2006-05-31
KR20030084894A (en) 2003-11-01
GT200100211A (en) 2002-08-19
EP1326864B1 (en) 2006-03-15
SK4602003A3 (en) 2004-11-03
NO20031582D0 (en) 2003-04-08
BRPI0114704B8 (en) 2021-05-25
CN1476448A (en) 2004-02-18
AU2002210796B8 (en) 2006-08-31
US20040181059A1 (en) 2004-09-16
JP2007277255A (en) 2007-10-25
EE200300188A (en) 2003-10-15
TNSN01145A1 (en) 2005-11-10
DE60118020D1 (en) 2006-05-11
EA200300387A1 (en) 2003-08-28
BR0114704A (en) 2004-02-25
AU2002210796B2 (en) 2006-08-10
HUP0303766A3 (en) 2005-07-28
CR6951A (en) 2003-11-25
ZA200302722B (en) 2004-04-08
ATE320428T1 (en) 2006-04-15
DOP2001000271A (en) 2001-11-18
ZA200302991B (en) 2004-04-16
CA2426487A1 (en) 2002-04-25
DE60118020T2 (en) 2006-08-24
BG107699A (en) 2003-12-31
OA12523A (en) 2006-05-30
HUP0303766A2 (en) 2004-04-28
CN101967146A (en) 2011-02-09
AU1079602A (en) 2002-04-29
WO2002032422A2 (en) 2002-04-25
PA8531001A1 (en) 2002-10-31
CN1477960A (en) 2004-02-25
CR6955A (en) 2004-02-02
US20020077329A1 (en) 2002-06-20
AP2003002806A0 (en) 2003-06-30
HN2001000224A (en) 2002-06-13
TW200716100A (en) 2007-05-01
TWI294424B (en) 2008-03-11
HRP20030269A2 (en) 2005-02-28
CA2426457A1 (en) 2002-04-25
EP1666480A1 (en) 2006-06-07
EP1326606A2 (en) 2003-07-16
PL362171A1 (en) 2004-10-18
US6710054B2 (en) 2004-03-23
KR100582319B1 (en) 2006-05-22
HUP0600593A2 (en) 2006-11-28
AU2001294122A1 (en) 2002-04-29
DZ3513A1 (en) 2002-04-25
UY26977A1 (en) 2002-06-20
PT1326864E (en) 2006-07-31
CY1105035T1 (en) 2010-03-03
ES2258554T3 (en) 2006-09-01
EP1666480B1 (en) 2014-10-01
PL365781A1 (en) 2005-01-10
WO2002032900A2 (en) 2002-04-25
JP2004511518A (en) 2004-04-15
GEP20053673B (en) 2005-11-25
WO2002032900A3 (en) 2002-08-08
US7479564B2 (en) 2009-01-20
IS6765A (en) 2003-03-31
CN101967146B (en) 2015-04-08
IL155439A0 (en) 2003-11-23
DK1326864T3 (en) 2006-06-19
KR20030048060A (en) 2003-06-18
MXPA03003448A (en) 2003-07-14
US7141580B2 (en) 2006-11-28
EP1326864A2 (en) 2003-07-16
NO20031658D0 (en) 2003-04-10
JP2004517054A (en) 2004-06-10
HUP0600593A3 (en) 2010-03-29
BRPI0114704B1 (en) 2015-08-18
US20070155732A1 (en) 2007-07-05
AP2001002299A0 (en) 2001-12-31
PE20020548A1 (en) 2002-06-20

Similar Documents

Publication Publication Date Title
GT200100211AA (en) COMPOSITES OF IMIDAZOL CONDENSED WITH ARILO OR HETEROARILO AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS. (PATENTEFRACTIONARY NO. 1 OF THE INVENTION PATENT APPLICATION NO. PI-2001-0211.
CO5261517A1 (en) ANALGESIC PHARMACEUTICAL COMPOSITIONS CONTAINING BUPRENORFINE / NALOXONE, BUPRENORFINE / NALTREXONE OR BUPRENORPHINE / NALMEFEN IN LOW DOSE
ES2156028T3 (en) Compositions containing tetrahydrolipstatin
PE20081799A1 (en) IMPROVEMENTS IN OR RELATED TO THE MEDICINAL COMPOSITIONS
AR032556A1 (en) IMMEDIATE ACTION DRUG FOR THE TREATMENT OF SEXUAL DYSFUNCTION
PA8513101A1 (en) DERIVATIVES OF ETERES DE PIRAZOL AS ANTI-INFLAMMATORY / ANALGESIC AGENTS
AR020001A1 (en) ACTIVATING COMPOUNDS OF hPPARGAMMA AND hPPARALFA, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, METHOD FOR THE TREATMENT AND / OR PREVENTION OF A DISEASE MEDIATED BY THE SAME, AND ITS USE FOR THE PREPARATION OF A MEDICINAL PRODUCT
PA8635901A1 (en) NUCLEOSIDS OF 3-BETA-D-RIBOFURANOSILTIAZOLO [4,5-D] PYRIMIDINE AND USES OF THE SAME
AR040248A1 (en) PHARMACO FOR THE TREATMENT OF HYPERACTIVE BLADDER
PA8508201A1 (en) HETEROCICLO-ALQUILSULFONIL PIRAZOLO DERIVATIVES AS ANTI-INFLAMMATORY / ANALGESIC AGENTS
PA8616201A1 (en) PHARMACEUTICAL COMPOSITIONS OF SUSTAINED LIBERATION
ATE440598T1 (en) ANALGESIC COMPOSITION OF TOPICALLY APPLIED NON-STEROID AND ANTI-INFLAMMATORY DRUGS AND OPIOIDS
AR003121A1 (en) ADHESION RECEPTOR ANTAGONISTS, PROCEDURE TO PREPARE THEM, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE TO PREPARE MEDICINES AND FIGHT DISEASES
AR045783A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING A P2X7 RECEIVER ANTAGONIST AND AN NON-STEROID ANTI-INFLAMMATORY DRUG
EA200600817A1 (en) ANTAGONISTS B1 BRADIKININ RECEPTOR (OPTIONS), PHARMACEUTICAL COMPOSITION, MEDICINAL MEDICINE, METHOD OF TREATMENT OF DISEASES (OPTIONS)
AR065582A1 (en) IMPROVEMENTS IN MEDICINAL COMPOSITIONS OR RELATED TO THE SAME
AR035946A1 (en) PHARMACEUTICAL COMPOSITIONS TO USE IN THE TREATMENT OF DISORDERS IN WOMEN PERIMENOPAUSIC, MENOPAUSIC OR POSMENOPAUSIC, AND USES OF SUCH COMPOSITIONS FOR THE PREPARATION OF MEDICINES
CO5261531A1 (en) PLEUROMUTILINE AND VALNEMULIN DERIVATIVES USED FOR THE MANUFACTURE OF A MEDICINAL PRODUCT IN THE TRANSDERMAL TREATMENT OF BACTERIAL INFECTIONS IN HUMANS AND ANIMALS AND COMPOSITION CONTAINING THEM
BR0014593A (en) Dosing unit for peroral administration
AR036009A1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF VISCERAL PAIN AND GASTROINTESTINAL DISORDERS THAT INCLUDE A BICYCLIC AMINO ACID COMPOUND AND USE OF THIS LAST TO MANUFACTURE SUCH PHARMACEUTICAL COMPOSITION
ES2182504T3 (en) BIFENILSULFONILCIANAMIDAS, PROCEDURE FOR ITS PREPARATION AND ITS USE AS A MEDICINAL PRODUCT.
JP2004534821A5 (en)
AR025521A1 (en) A PERCUTANEOUS THERAPEUTIC SYSTEM CONSTITUTED BY A BACK LAYER, AT LEAST A MATRIX COAT CONTAINING ACTIVE PRINCIPLE, THAT MAY ALSO HAVE SELF-ADHESIVE PROPERTIES, AS WELL AS SEPARABLE PROTECTION LAYER
AR008083A1 (en) PHARMACEUTICAL COMPOSITIONS AND THE USE OF COMPOUNDS TO PREPARE DRUGS TO TREAT CNS DISORDERS.
GT200000087A (en) POLYMORPH FORMS OF A AZABICICLO CITRATE (2.2.2) OCTAN - 3 - AMINA AND ITS PHARMACEUTICAL COMPOSITIONS.